MAY 09, 2019 9:00 AM PDT

Polygenic Risk Scores: PheWas and GWAS and Utility of Biobank Information

Sponsored by: Illumina
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Associate Professor, Director, Genetic and Molecular Epidemiology Laboratory, McMaster Genome Institute
    Biography
      Guillaume Pare is an Associate Professor and University Scholar, Dept. of Pathology & Molecular Medicine at McMaster University and Director of the Genetic and Molecular Epidemiology Laboratory. He was recently inducted as a member into the Royal Society of Canada's College of New Scholars, Artists and Scientists. In 2018, AHA selected his publication (Theriault et al., Circ Genom Precis Med 11:e001849, 2018) as one of the 'Top 10 Advances in Cardiovascular Research in 2018'. Dr. Pare currently holds a Canada Research Chair in Genetic & Molecular Epidemiology, as well as a CISCO Professorship. His clinical interests are centered on lipoprotein disorders, obesity and cardiovascular disease prevention. His corresponding research interests are in cardiovascular genetics, biomarker development and pharmacogenomics. These interests have led to expertise in bioinformatics, high-throughput biology and genetic epidemiology. Since joining McMaster University in 2009, Dr. Pare has published over 190 original contributions in peer-reviewed journals, all related to his research program in cardiovascular disease and genetics. These include first or last authored articles in the NEJM, Lancet (comment), Circulation, EHJ, Stroke, JACC, PLoS Genetics, Circulation Genetics and Scientific Reports. Collectively, he has published 207 peer-reviewed manuscripts, which have been cited over 21,000 times.

    Abstract

    The advent of precision medicine largely depends on the creation of precise and accurate predictive tools. While most late-onset diseases are moderately to highly heritable, using genetic information to make individual predictions about risk of disease has proven to be challenging. Recent technological and methodological advances have established the importance of the polygenic model of inheritance for complex diseases, whereby dozens of thousands of functional variants might contribute to disease risk. Genome-wide association studies have identified thousands of variants associated with disease, yet each individual variant tends to only have a modest effect on risk. We and others have proposed using polygenic risk scores combining information from hundreds to millions of variants to improve genetic risk prediction and identify individuals at very high risk of disease.  We illustrate this approach by studying coronary artery disease (CAD), a leading cause of mortality worldwide. A genetic cause is identified in less than 5% of patients with early onset disease, mainly Mendelian mutations leading to Familial Hypercholesterolemia. Our data show that belonging to the extreme tail of polygenic risk is associated with a greater risk of CAD than carrying a Mendelian mutation, both in terms of risk and prevalence. Indeed, more individuals are at high risk of CAD because of polygenic risk, and such individuals have higher risk than carriers of routinely tested Familial Hypercholesterolemia mutations. Similar findings have been reported for other common diseases such as breast and prostate cancer, among others. These findings support clinical use of polygenic risk scores for common complex disease in the near future.

    Learning Objectives: 

    1. Understand the polygenic nature of complex traits
    2. Understand principles of polygenic risk scores
    3. Clinical applications of polygenic risk scores


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    MAY 09, 2019 9:00 AM PDT

    Polygenic Risk Scores: PheWas and GWAS and Utility of Biobank Information

    Sponsored by: Illumina
    C.E. Credits: P.A.C.E. CE Florida CE

    No demographic data is available yet for this event.


    Show Resources
    Loading Comments...
    Show Resources